Obesity‑care guidelines reviewed

Obesity guidelines are starting to look less like a diet handout and more like a long-term care plan, because the field now treats body weight the way it treats blood pressure: something to measure, stage, and manage over time. A new review in The American Journal of Managed Care pulls together the main guidance doctors are actually using, from older 2013 and 2016 standards to newer medication updates. (ajmc.com) The first building block is body mass index, which is a height-and-weight screening tool, not a full diagnosis by itself. The Centers for Disease Control and Prevention says adult obesity starts at a body mass index of 30, but also says the number should be interpreted alongside other health factors. (cdc.gov) That distinction matters because newer obesity care is not just asking, “How high is the number on the scale?” The 2016 American Association of Clinical Endocrinologists and American College of Endocrinology guideline pushed doctors to look at weight-related complications, so treatment is matched to problems like diabetes, sleep apnea, or high blood pressure, not to a single universal target. (pro.aace.com) Lifestyle treatment still sits at the center of every major guideline. The AJMC review says nutrition, physical activity, and behavior change remain the cornerstone, even when medication or surgery gets added later. (ajmc.com) Medication enters the picture when lifestyle changes alone have not produced enough improvement. The American Gastroenterological Association’s 2022 guideline recommends adding drug therapy for adults with obesity, or for adults who are overweight and already have weight-related complications, instead of continuing lifestyle treatment alone. (gastro.org) Those drug recommendations are much more specific than they were a decade ago. The same 2022 guideline suggests semaglutide 2.4 milligrams and liraglutide 3.0 milligrams, along with older options like phentermine-topiramate extended release and naltrexone-bupropion extended release, while suggesting against orlistat. (gastro.org) Semaglutide changed the conversation because the Food and Drug Administration approved Wegovy on June 4, 2021, for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition. That approval was the first new chronic weight-management drug approval since 2014. (fda.gov) The older Endocrine Society guidance shows how doctors are supposed to judge whether a drug is worth staying on. Its 2016 recommendation says to continue a weight-loss medication if a patient loses at least 5 percent of body weight after 3 months, and to stop or switch if the drug is ineffective or causes side effects. (endocrine.org) Surgery is also moving inside the same guideline framework instead of sitting off to the side as a last-resort option. The 2022 joint guidance from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity says metabolic and bariatric surgery is recommended for people with a body mass index of 35 or more, regardless of whether obesity-related conditions are present, and should be considered starting at 30 for people who do not get durable results with nonsurgical treatment. (asmbs.org) Under all of this is a shift in how medicine defines the problem. The American Medical Association voted in June 2013 to recognize obesity as a chronic disease, and the AJMC review treats that decision as the starting point for today’s more standardized care pathways. (ama-assn.org) (ajmc.com) So the big change is not that doctors suddenly discovered obesity in 2026. It is that the field now has a more settled playbook: screen with body mass index, check for complications, start with lifestyle treatment, add medication when needed, and use surgery earlier for the right patients instead of waiting until every other option has failed. (ajmc.com) (gastro.org) (asmbs.org)